In today’s briefing:
- Japan Weekly | Nitori, Renova, SMM
- Changan JVs Plan to Accelerate EV Transition as Conventional Cars Lose Position
- Commercial/Contract Furniture/Consumer Hardlines : Orders Remain Lower Y/Y, but at Moderating Pace
- Shroom Shmooz – Overview of the Clinical Trial Landscape in Psychedelics
Japan Weekly | Nitori, Renova, SMM
- The Japanese stock market remains in an uptrend with the Nikkei hitting a 17-month high
- Global growth expectations remain weak. Key commodity prices lower on weakness in the Chinese economic outlook
- Stocks in Japan moving mainly on earnings reports. Same again next week
Changan JVs Plan to Accelerate EV Transition as Conventional Cars Lose Position
- Chongqing Changan Automobile Co. Ltd. plans to speed up the electrification of two of its joint ventures with foreign carmakers, as China’s homegrown electric-vehicle brands increasingly gain market share from fossil fuel-powered car companies.
- The change in the industry was laid bare at last month’s Shanghai Auto Show, where the booths of Chinese brands were flooded with visitors.
- A decade ago, cars built by China’s numerous international JVs would typically be center stage at such exhibitions.
Commercial/Contract Furniture/Consumer Hardlines : Orders Remain Lower Y/Y, but at Moderating Pace
- This note addresses the Monthly Market Pulse (MMP) of incoming orders and sales for March 2023 issued by the Business Institutional Furniture Manufacturers Association (BIFMA).
- About 50+ BIFMA member companies voluntarily submit monthly sales and orders to a national accounting firm that aggregates and reports composite data.
- Neither BIFMA nor any individual member has access to the raw data. We show the monthly data from 2019 to March 2023 under Industry Statistics.
Shroom Shmooz – Overview of the Clinical Trial Landscape in Psychedelics
- The clinical trial landscape in psychedelics has evolved significantly over the past five years and has seen significant developments and milestones achieved in the last year.
- There are currently more than 50 active clinical trials investigating the therapeutic value of psychedelic-based compounds as part of a treatment regimen, which includes the more traditional psychotherapy intervention.
- About 60% of these clinical investigations have advanced to Phase II and Phase III stage trials.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
